SOURCE: Equity Markets Inc

September 19, 2011 09:00 ET

Global Situation & Resulting Influences - Research Report on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)

MACAU--(Marketwire - Sep 19, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Keryx Biopharmaceuticals (NASDAQ: KERX) and AEterna Zentaris Inc. (USA) (NASDAQ: AEZS). Full content and research is available at www.EquityMarketsInc.com/research.php?id=KERX+AEZS.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Keryx Biopharmaceuticals for its current position within the healthcare industry. Keryx Biopharmaceuticals, Inc. (Keryx)is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. The full research report on Keryx Biopharmaceuticals (NASDAQ: KERX) is available here: www.EquityMarketsInc.com/research.php?id=KERX.

World Street has featured AEterna Zentaris Inc. (USA) for its development within the healthcare industry. AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The full research report on AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) is available here: www.EquityMarketsInc.com/research.php?id=AEZS.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information